Ipca Laboratories partners with Medicines for Malaria Ventur

For co-developing a novel antimalarial co-formulation named 'Atoguanil'

Ipca Laboratories has entered into an agreement with a leading product development partnership, Medicines for Malaria Venture (MMV), to co-develop a novel antimalarial co-formulation named "Atoguanil".

Atoguanil, based on proprietary Ipca technology, contains the active pharmaceutical ingredients atovaquone and proguanil. Today, the manufacturing cost of atovaquone is believed to pose a barrier to widespread use of atovaquone-proguanil based products in malaria-endemic countries. Atoguanil has the potential to provide a lower cost alternative, making such products more accessible to people living in malaria-endemic countries for prophylaxis.

Powered by Capital Market - Live News